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Abstract We report a new tumor-directed immunoRNase, a
chimeric protein made up of an antibody fragment (single-chain
Fv fragment) directed to ErbB2, a cell surface receptor, and a
non-toxic, human ribonuclease, which upon cell internalization
becomes cytotoxic. The immunoRNase is active as a ribonu-
clease, specifically binds and selectively kills ErbB2-positive
cells. ErbB2 is one of the most specific tumor-associated antigens
identified so far, overexpressed on tumor cells of different origin.
Its choice as target antigen and that of a non-toxic, human
RNase as the killer moiety makes this immunoRNase a new,
potentially attractive anticancer agent. ß 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Conventional anticancer treatments, such as radiation and
systemic drugs, are characterized by the lack of tumor cell
speci¢city. An alternative strategy is that based on immuno-
toxins, fusion molecules designed to kill only target cells. Im-
munotoxins have been shown to kill cancer cells with IC50
(the concentration for 50% cytotoxicity) in the 0.01^1 nM
range [1,2]. However, problems have been encountered in clin-
ical trials, especially for the toxicity and immunogenicity of
the powerful bacterial or plant cytotoxins used for construct-
ing immunotoxins [3,4].
A more recent strategy is that based on immunoconjugates,
or ‘immunoRNases’ (IR), in which the toxin is replaced by an
RNase molecule. The key to the IR strategy is that RNases,
although per se not cytotoxic, become cytotoxic when they are
internalized by the target cell, i.e. the cell that displays on its
surface the epitope recognized by the antibody moiety [3].
This is why the most suitable epitopes for the selection of
an antibody for IR are cell receptors, since the anti-receptor
antibody can mimic the receptor ligand and be internalized.
The ¢rst IR has been prepared with bovine pancreatic RNase
A [5], fused to an anti-transferrin receptor antibody, and
shown to be cytotoxic to tumor cells expressing the transferrin
receptor in the 200^500 nM range.
The immunocompatibility of IRs as anticancer agents can
be greatly improved by the use of human RNases, as they are
physiologically present in extracellular £uids and tissues, and
are expected to be much less immunogenic than xenogeneic
proteins, if not immunogenic at all. On the other hand, in an
immunotoxin or an IR antibodies can be replaced by single-
chain variable fragments (scFv), which can easily penetrate
solid tumors, fully preserving the speci¢city of the parental
antibody. IRs, made up of human RNases fused to an anti-
transferrin receptor scFv, have been prepared (see [3] for a
review, and references therein). These IRs were cytotoxic to
tumor cells with IC50 in the 5^20 nM range. However, the
abundance of the transferrin receptor at the blood^brain bar-
rier, which can result in the uptake of high amounts of these
immunoconjugates by the brain, sets a limit to the use of these
reagents as therapeutic drugs [6].
An attractive target for IR-based, directed tumor therapy is
the ErbB2 transmembrane receptor. A member of the ErbB
superfamily of growth factor tyrosine kinase receptors [7],
ErbB2 is highly expressed on several tumor cells, especially
in breast, ovary and lung carcinomas [8,9], and is implicated
in the development of malignancy [10]. Conversely, in normal
tissues it is expressed at low levels, and only in certain epithe-
lial cell types [11]. Furthermore, ErbB2 is internalized upon
ligand binding, an event which can be mimicked by an anti-
body directed towards the receptor, thus it is an appropriate
target for delivering RNases into ErbB2-overexpressing tumor
cells. Herceptin [12,13], an anti-ErbB2 monoclonal antibody,
has proved to be an e¡ective anticancer drug in clinical anti-
cancer therapy.
In this report we describe the construction and character-
ization of a new, anti-ErbB2 IR, named ERB-HPR, con-
structed by fusing human pancreas RNase (HP-RNase) to
an anti-ErbB2 scFv. We found that HP-RNase, by itself not
cytotoxic, when fused to the anti-ErbB2 scFv acquires a se-
lective cytotoxic activity towards antigen-bearing cell lines.
2. Materials and methods
2.1. Construction, expression and puri¢cation of ERB-HPR
The cDNA encoding the anti-ErbB2 scFv [14] was cloned in a
pRSET-a vector (Invitrogen), which includes sequences encoding six
histidines and the Xpress peptide, both positioned upstream of the
scFv cDNA. The recombinant vector was linearized with EcoRI;
protruding ends were then ¢lled in by T4 bacteriophage DNA poly-
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merase. By digestion with HindIII a linear blunt-ended/HindIII re-
combinant vector was generated.
The cDNA encoding HP-RNase [15], cloned in the NdeI/HindIII
restriction sites of a pET 22b+ vector, was digested with NdeI and
treated with the T4 bacteriophage DNA polymerase to create blunt
ends; the linearized DNA was then digested with HindIII to generate
a blunt-ended/HindIII fragment. This was inserted into the linearized
vector downstream of the cDNA encoding the anti-ErbB2 scFv frag-
ment described above. In the resulting chimeric DNA, a sequence
encoding a spacer (GSPEFM) is interposed between the scFv and
RNase moieties. The recombinant plasmid was used to transform
Escherichia coli B834(DE3)pLysS (Novagen) competent cells.
Freshly transformed cells, grown in LB medium containing 0.5%
glucose, 50 Wg/ml ampicillin and 30 Wg/ml chloramphenicol to an
OD600 of 1.0, were centrifuged at 6000 rpm for 15 min and suspended
in glucose-free medium to allow the expression of the fusion protein,
induced with 0.4 mM IPTG for 16 h. Cells were harvested by centri-
fugation at 6000 rpm for 15 min at 4‡C. The cell lysate was obtained
according to the Xpress Puri¢cation System protocol (Invitrogen),
and loaded on a ProBond1 resin (Invitrogen) to purify the recombi-
nant protein via binding of the His tag to Ni2 ions. Bound proteins,
eluted following the manufacturer’s instructions, were reduced with
0.1 M glutathione in the elution bu¡er, previously adjusted to pH 8.4.
After 2.5 h at room temperature, the proteins were diluted with 20
volumes of 0.1 M Tris^acetate, at pH 8.4, containing 0.5 M L-arginine
and 1 mM oxidized glutathione, and allowed to reoxidize for 24 h at
room temperature. Proteins were then concentrated and dialyzed
against 50 mM Tris^HCl, at pH 8.0, containing 0.25 M NaCl, 10%
glycerol and 0.005% Tween 20.
Further puri¢cation was achieved by a⁄nity chromatography using
uridine 2P,5P- and 3P,5P-diphosphate agarose (pUp agarose, Sigma).
Brie£y, the sample was adjusted to pH 5.8 and loaded on the column,
previously equilibrated in 0.1 M sodium acetate bu¡er at pH 5.8,
containing 0.15 M NaCl, 10% glycerol and 0.005% Tween 20. After
extensive washing with the equilibrium bu¡er, the protein was eluted
in phosphate-bu¡ered saline (PBS) containing 0.5 M NaCl, 10% glyc-
erol and 0.005% Tween 20. The puri¢ed protein was analyzed by
SDS^PAGE and quantitated by BCA assays (Pierce).
2.2. RNase activity assays
RNase activity was tested as previously described [16] on yeast
RNA (Sigma) (8 mg/ml). Zymograms were performed as described
in [17].
2.3. ELISA assays
SKBR3 and A431 cells (kindly provided by Menarini Research,
Italy), grown in RPMI 1640 with 10% fetal calf serum on 96-well
plates, were ¢xed with 2% formaldehyde in PBS (3.3U104 cells/
well). After treatment with 3% bovine serum albumin (Sigma) in
PBS, serial dilutions of the IR (in the concentration range 10^500
nM) were added in a ¢nal volume of 100 Wl of PBS containing 3%
bovine serum albumin, and the plates were incubated for 1 h at 37‡C.
Speci¢cally bound ERB-HPR was detected after incubation either
with a murine anti-Xpress peptide monoclonal antibody (mAb; Invi-
trogen), or with a rabbit anti-HP-RNase antibody (Igtech), followed
by goat alkaline phosphatase-conjugated anti-mouse IgG, or by anti-
rabbit IgG (both from Sigma), according to the source of the primary
antibody. The phosphatase reaction product was measured as absor-
bance at 405 nm, and the values are expressed as the mean of at least
three determinations (S.D.95%).
2.4. Western blot analyses
To prepare cell lysates, about 6U105 cells, detached from the plates
with the Sigma cell dissociation solution, were washed three times in
PBS and suspended in 0.3 ml of lysis bu¡er made up of 10 mM Tris^
HCl, pH 7.4, 150 mM NaCl and 0.5% Nonidet P-40 containing Com-
plete1 protease inhibitors (Boehringer Mannheim). After 20 min at
0‡C, the extracts were clari¢ed by centrifugation at 12 000 rpm for 15
min. Protein concentration was determined by a colorimetric assay
(Bradford, Sigma), and aliquots of 20 Wg were run on 7.5% SDS^
PAGE, followed by electroblotting onto polyvinylidene di£uoride
membranes (Millipore). The ErbB2 protein was detected using
the anti-ErbB2 MgR6 mAb [18], followed by rabbit anti-mouse
HRP-conjugated IgG (NEN). The signal intensity of reactive
bands was quantitatively measured with a phosphorimager (GS-710,
Bio-Rad). The data were normalized to those obtained for the same
extracts using an anti-actin mAb.
2.5. Cytotoxicity assays
SKBR3 and MDA-MB453 cells (a gift of H.C. Hurst, ICRF, Lon-
don, UK) were seeded in 96-well plates at a density of 1.5U104/well in
150 Wl ; A431, at a density of 5U103/well. Proteins under test were
added, and after 72 h cell counts were determined in triplicate using
the trypan blue exclusion test. In parallel experiments, cells were
pulsed for 3 h with [3H]leucine (Amersham Pharmacia Biotech) prior
to harvesting, and the incorporated radioactivity was measured. Cell
survival is expressed as percent viable cells in the presence of the
protein under test relative to control cultures grown in the absence
of the protein. Typically, standard deviations were below 5%.
3. Results and discussion
3.1. Construction and puri¢cation of ERB-HPR
The cDNA encoding an anti-ErbB2 scFv fragment [14],
obtained from mAb MgR6 [18], was fused to the 5P-end of
the cDNA encoding HP-RNase [15]. A scheme of the protein
chimera is shown in Fig. 1. At its N-terminus it contains a
short peptide (Xpress peptide, Invitrogen) linked downstream
to an a⁄nity tag of six histidine residues. Between VH and VL
chains of the scFv a 15-residue linker, made up of glycine and
serine (G4S)3, is interposed, and a six-residue spacer is in-
serted between the antibody fragment and the ribonuclease
to minimize hindrance between the two moieties of the chi-
meric protein. The scFv was linked to the N-terminus of HP-
RNase as this is more solvent-accessible than the C-terminus
[19].
The chimeric cDNA was fully sequenced, cloned in a T7
promoter-based E. coli expression vector (pRSET-a), and ex-
pressed at high levels as an insoluble protein sequestered in
inclusion bodies. The inclusion bodies were denatured and the
recombinant fusion protein was puri¢ed under denaturing
conditions on an immobilized-metal a⁄nity chromatography
by using a nickel-chelating resin. After refolding, carried out
in the presence of a glutathione redox bu¡er, RNase activity
was recovered in suitable amounts (170 U/ml of culture me-
dium).
The IR, named ERB-HPR, was further puri¢ed by a second
a⁄nity chromatography using pUp agarose (see Section 2).
Analysis by SDS^PAGE indicated that the recombinant pro-
tein was homogeneous (see Fig. 2). The yield was approxi-
mately 5 mg/l culture.
3.2. Characterization of ERB-HPR
The puri¢ed fusion protein was analyzed by Western blot-
ting with either an anti-Xpress peptide or an anti-HP-RNase
antibody. By both analyses a band of the expected size (ap-
proximately 46 kDa) was visualized (Fig. 2).
By a zymogram assay (see Fig. 2), and a standard RNase
assay in solution, ERB-HPR was found to be active, with a
speci¢c activity of 800 U/nmol, i.e. more than 70% of the
activity of the original RNase molecule. These results, when
compared to previous reports on RNase activity of other IRs
[3,20], appear to be highly satisfactory.
The ability of ERB-HPR to speci¢cally recognize ErbB2
was measured by ELISA assays using SKBR3 cells from hu-
man breast cancer, which overexpress ErbB2, and A431 cells
from human epidermoid carcinoma, which express the recep-
tor at very low levels. The results of these experiments (see
Fig. 3) indicate that the IR e¡ectively binds SKBR3 cells,
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whereas it binds poorly to A431 cells. The apparent binding
a⁄nity of ERB-HPR for the ErbB2 receptor, i.e. the concen-
tration corresponding to half-maximal saturation, was found
to be 15 nM. In parallel experiments, this value was found to
be comparable to that measured per single antigen binding
site on the parental MgR6 mAb (see Fig. 3).
It is not easy to explain how monovalent ERB-HPR and
bivalent MgR6 have comparable binding a⁄nities. Besides the
possibility that the anti-ErbB2 scFv has an intrinsic high af-
¢nity for the antigen, we cannot exclude that the presence of
the RNase in the chimeric molecule induces further stabilizing
interactions between the scFv and the antigen.
By size exclusion fast liquid chromatography on a Superdex
200 column, ERB-HPR was found to be stable as a monomer
(data not shown), with a relative molecular mass of approx-
imately 46 kDa, in line with the value obtained by SDS^
PAGE (see above).
3.3. Cytotoxic e¡ects on tumor cells
The ¢nding that ERB-HPR is endowed with both RNase
activity and antigen binding speci¢city led us to investigate
whether it could also inhibit the growth of cells overexpressing
ErbB2. ERB-HPR was tested for its e¡ects on antigen-posi-
tive (SKBR3 and MDA-MB453 cell lines, both derived from
breast carcinomas) and antigen-negative cell lines (A431 cells).
Cells were plated in the absence or in the presence of increas-
ing concentrations of ERB-HPR, and incubated for 72 h. Cell
survival was measured either by counting trypan blue-exclud-
ing cells, or by measuring protein synthesis. In parallel experi-
ments, the e¡ects on cell survival of recombinant wild-type
HP-RNase and of the parental anti-ErbB2 mAb MgR6 were
also tested.
As shown in Fig. 4A, ERB-HPR was found by trypan blue
exclusion test to be selectively cytotoxic for ErbB2-overex-
pressing cells, and in a dose-dependent manner. The IC50
values were found to be 50 and 120 nM for SKBR3 and
MDA-MB453 cells, respectively. No e¡ects on the growth of
A431 cells were detected (see Fig. 4A). Moreover, no e¡ects
on cell survival were detected when either free HP-RNase (see
Fig. 4A) or the parental MgR6 mAb (see Fig. 5) was tested on
SKBR3 cells. These ¢ndings indicate that the IR ERB-HPR is
a powerful cytotoxic agent, selective for ErbB2-bearing cells.
When the experiments were repeated by measuring protein
synthesis of treated versus untreated cells, identical results
were obtained (data not shown).
To investigate the higher cytotoxicity of ERB-HPR on the
SKBR3 cell line, compared to that on MDA-MB453 cells, and
the lack of cytotoxicity on A431 cells, a quantitative analysis
by Western blotting was performed on lysates from the three
cell types, tested for their ErbB2 levels with the parental anti-
ErbB2 mAb. The positive bands were analyzed with a phos-
phorimager, and the corresponding signal intensities were nor-
malized to those obtained in the same lysates by an anti-actin
antibody. The results of these experiments (Fig. 4B) show that
the level of ErbB2 determined in MDA-MB453 cells is about
six-fold lower than that measured in SKBR3 cells. No positive
band corresponding to ErbB2 was detectable instead in A431
cells (see Fig. 4B). These results indicate that there is a strict
Fig. 1. Schematic representation of the IR ERB-HPR. (His)6 is the
six-residue His tag; Xpress is the peptide recognized by the anti-
Xpress mAb; VH and VL, the variable domains of the heavy and
light chains, respectively, of the anti-ErbB2 scFv; L, the 15-residue
linker (G4S)3 ; S, the six-residue spacer (GSPEFM); HP, HP-RNase.
Fig. 2. Analyses by SDS^PAGE of crude and puri¢ed ERB-HPR.
Lane 1, cell extract from inclusion bodies; lane 2, ERB-HPR (10
Wg) eluted from the a⁄nity chromatography on pUp agarose; lanes
3 and 4, Western blot analyses of ERB-HPR (100 ng), using the
anti-Xpress mAb (lane 3), or the anti-HP-RNase IgGs (lane 4); lane
5, a zymogram of ERB-HPR (120 ng), using yeast RNA as a sub-
strate.
Fig. 3. Binding curves of ERB-HPR to ErbB2-positive (SKBR3)
and -negative (A431) cell lines. SKBR3 cells were tested by ELISA
assays with ERB-HPR (black circles), or with the anti-ErbB2 MgR6
mAb (white circles), as a control; A431 cells were tested with ERB-
HPR or MgR6 mAb (black and white squares, respectively).
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correlation between levels of expression of ErbB2 on a cell
surface and sensitivity of that cell to ERB-HPR.
The speci¢city of ERB-HPR for target cells was con¢rmed
when its cytotoxic activity was determined on SKBR3 cells in
the presence of the parental anti-ErbB2 MgR6 mAb. As
shown in Fig. 5, MgR6 was found to reverse the inhibitory
e¡ect of ERB-HPR on SKBR3 cell growth. When the molar
excess of MgR6 (290 nM) over ERB-HPR (150 nM) was
about two-fold, more than 50% of ERB-HPR cytotoxicity
was lost. When a four-fold molar excess was reached, by low-
ering the ERB-HPR concentration to 75 nM, the toxicity of
the IR was found to be fully suppressed (see Fig. 5). These
results demonstrate that ERB-HPR and the parental anti-
ErbB2 mAb compete for the same site on SKBR3 cells, and
con¢rm that the cytotoxic action of the IR depends on its
speci¢c recognition of ErbB2.
These results also indicate that ERB-HPR interacts with the
antigen and is internalized even in its monovalent form. This,
however, may not be surprising, since it has been reported
that the parental mAb is e¡ectively internalized by ErbB2-
overexpressing cells [18]. Furthermore, Poul and colleagues
have recently isolated a panel of monovalent scFv that can
be internalized, including scFv speci¢c for ErbB2 [21].
To our knowledge, ERB-HPR is the ¢rst IR directed to
ErbB2 to be reported to date. Based on the e¡ectiveness
and selectivity of its cytotoxic action on target cells, it repre-
sents a potentially valuable tool in cancer immunotherapy.
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Fig. 4. E¡ects of ERB-HPR on cell survival. A: Dose^response
curves determined for SKBR3 (black circles), MDA-MB453 (trian-
gles), and A431 cell lines (squares), upon treatment for 72 h with
ERB-HPR. SKBR3 cells were also tested with native HP-RNase
(white circles). B: Western blot analyses of the expression levels of
ErbB2 in the indicated cell lines, determined using the anti-ErbB2
MgR6 mAb. To normalize the band signals, an anti-actin mAb was
used in the same experiments.
Fig. 5. Dose^response curves of SKBR3 cells treated with ERB-
HPR in the absence (black circles) or in the presence of 290 nM
anti-ErbB2 MgR6 mAb (white circles). The dose^response curve ob-
tained with the anti-ErbB2 MgR6 mAb alone (squares) is also
shown.
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